{"id":"NCT00790933","sponsor":"Takeda","briefTitle":"An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease","officialTitle":"A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05-22","primaryCompletion":"2017-10-31","completion":"2017-10-31","firstPosted":"2008-11-14","resultsPosted":"2019-03-12","lastUpdate":"2022-05-24"},"enrollment":2243,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Ulcerative Colitis","Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Vedolizumab","otherNames":["MLN0002"]}],"arms":[{"label":"Vedolizumab 300 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.","primaryOutcome":{"measure":"Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to approximately 8.5 years)","effectByArm":[{"arm":"Vedolizumab 300 mg (UC)","deltaMin":93,"sd":null},{"arm":"Vedolizumab 300 mg (CD)","deltaMin":96,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":41,"countries":["United States","Australia","Belgium","Canada","Czechia","Germany","Hungary","Israel","Malaysia","South Korea"]},"refs":{"pmids":["35934286","33908636","32876349","30365009","27802155","26893500"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":825,"n":2243},"commonTop":["Nasopharyngitis","Arthralgia","Headache","Abdominal pain","Upper respiratory tract infection"]}}